499 related articles for article (PubMed ID: 32482755)
21. Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.
Skarzynski M; Niemann CU; Lee YS; Martyr S; Maric I; Salem D; Stetler-Stevenson M; Marti GE; Calvo KR; Yuan C; Valdez J; Soto S; Farooqui MZ; Herman SE; Wiestner A
Clin Cancer Res; 2016 Jan; 22(1):86-95. PubMed ID: 26283682
[TBL] [Abstract][Full Text] [Related]
22. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
23. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
[TBL] [Abstract][Full Text] [Related]
24. The future of CD20 monoclonal antibody therapy in B-cell malignancies.
Czuczman MS; Gregory SA
Leuk Lymphoma; 2010 Jun; 51(6):983-94. PubMed ID: 20367564
[TBL] [Abstract][Full Text] [Related]
25. The Enhanced Cytotoxic Effects in B-Cell Leukemia and Lymphoma Following Activation of Prostaglandin EP4 Receptor and Targeting of CD20 Antigen by Monoclonal Antibodies.
Markovič T; Podgornik H; Avsec D; Nabergoj S; Mlinarič-Raščan I
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163524
[TBL] [Abstract][Full Text] [Related]
26. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
Cramer P; von Tresckow J; Eichhorst B; Hallek M
Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
[TBL] [Abstract][Full Text] [Related]
27. The HDAC inhibitor valproate induces a bivalent status of the CD20 promoter in CLL patients suggesting distinct epigenetic regulation of CD20 expression in CLL in vivo.
Scialdone A; Hasni MS; Damm JK; Lennartsson A; Gullberg U; Drott K
Oncotarget; 2017 Jun; 8(23):37409-37422. PubMed ID: 28445158
[TBL] [Abstract][Full Text] [Related]
28. Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.
Robak T
Expert Rev Hematol; 2014 Dec; 7(6):841-57. PubMed ID: 25249370
[TBL] [Abstract][Full Text] [Related]
29. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
30. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
Hallek M
Am J Hematol; 2015 May; 90(5):446-60. PubMed ID: 25908509
[TBL] [Abstract][Full Text] [Related]
31. Transient antagonism of anti-CD20 monoclonal antibodies and PI3K inhibitor idelalisib in DLBCL cell lines.
Zoellner AK; Peter N; Zimmermann Y; Hutter G; Hiddemann W; Dreyling M
Eur J Haematol; 2018 Apr; ():. PubMed ID: 29617050
[TBL] [Abstract][Full Text] [Related]
32. Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target.
Morabito F; Gentile M; Seymour JF; Polliack A
Leuk Lymphoma; 2015; 56(12):3250-6. PubMed ID: 26062943
[TBL] [Abstract][Full Text] [Related]
33. BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL.
Rogers A; Woyach JA
Ther Adv Hematol; 2020; 11():2040620720912990. PubMed ID: 32231778
[TBL] [Abstract][Full Text] [Related]
34. IRF8 regulates efficacy of therapeutic anti-CD20 monoclonal antibodies.
Grzelak L; Roesch F; Vaysse A; Biton A; Legendre R; Porrot F; Commère PH; Planchais C; Mouquet H; Vignuzzi M; Bruel T; Schwartz O
Eur J Immunol; 2022 Oct; 52(10):1648-1661. PubMed ID: 36030374
[TBL] [Abstract][Full Text] [Related]
35. Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.
Sanford DS; Wierda WG; Burger JA; Keating MJ; O'Brien SM
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):385-91. PubMed ID: 25817936
[TBL] [Abstract][Full Text] [Related]
36. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59.
Golay J; Lazzari M; Facchinetti V; Bernasconi S; Borleri G; Barbui T; Rambaldi A; Introna M
Blood; 2001 Dec; 98(12):3383-9. PubMed ID: 11719378
[TBL] [Abstract][Full Text] [Related]
37. Escape mechanisms from antibody therapy to lymphoma cells: downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation.
Sugimoto T; Tomita A; Hiraga J; Shimada K; Kiyoi H; Kinoshita T; Naoe T
Biochem Biophys Res Commun; 2009 Dec; 390(1):48-53. PubMed ID: 19769942
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with
Yoon JT; Longtine MS; Marquez-Nostra BV; Wahl RL
J Nucl Med; 2018 Aug; 59(8):1219-1224. PubMed ID: 29348316
[TBL] [Abstract][Full Text] [Related]
39. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism.
Pedersen IM; Buhl AM; Klausen P; Geisler CH; Jurlander J
Blood; 2002 Feb; 99(4):1314-9. PubMed ID: 11830481
[TBL] [Abstract][Full Text] [Related]
40. Genetic and Epigenetic Modulation of CD20 Expression in B-Cell Malignancies: Molecular Mechanisms and Significance to Rituximab Resistance.
Tomita A
J Clin Exp Hematop; 2016; 56(2):89-99. PubMed ID: 27980307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
